nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A1—liver cancer	0.396	0.642	CbGaD
Sulindac—ALB—liver cancer	0.22	0.358	CbGaD
Sulindac—Prothrombin level increased—Epirubicin—liver cancer	0.00137	0.0109	CcSEcCtD
Sulindac—Gynaecomastia—Sorafenib—liver cancer	0.00136	0.0108	CcSEcCtD
Sulindac—Prothrombin level increased—Doxorubicin—liver cancer	0.00127	0.01	CcSEcCtD
Sulindac—Hepatic failure—Sorafenib—liver cancer	0.00123	0.00974	CcSEcCtD
Sulindac—Cardiac failure congestive—Sorafenib—liver cancer	0.00122	0.00965	CcSEcCtD
Sulindac—Dermatitis exfoliative—Sorafenib—liver cancer	0.00117	0.00927	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.000995	0.00788	CcSEcCtD
Sulindac—Gastritis—Sorafenib—liver cancer	0.000978	0.00774	CcSEcCtD
Sulindac—Pancreatitis—Sorafenib—liver cancer	0.000936	0.00741	CcSEcCtD
Sulindac—Neutropenia—Sorafenib—liver cancer	0.000893	0.00707	CcSEcCtD
Sulindac—Pneumonia—Sorafenib—liver cancer	0.000856	0.00678	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.000844	0.00668	CcSEcCtD
Sulindac—Renal failure—Sorafenib—liver cancer	0.000837	0.00663	CcSEcCtD
Sulindac—Neuropathy peripheral—Sorafenib—liver cancer	0.000835	0.00661	CcSEcCtD
Sulindac—Bone marrow depression—Epirubicin—liver cancer	0.000833	0.0066	CcSEcCtD
Sulindac—Jaundice—Sorafenib—liver cancer	0.00083	0.00657	CcSEcCtD
Sulindac—Stomatitis—Sorafenib—liver cancer	0.00083	0.00657	CcSEcCtD
Sulindac—Epistaxis—Sorafenib—liver cancer	0.000803	0.00636	CcSEcCtD
Sulindac—Bone marrow depression—Doxorubicin—liver cancer	0.000771	0.00611	CcSEcCtD
Sulindac—Vaginal haemorrhage—Epirubicin—liver cancer	0.00076	0.00602	CcSEcCtD
Sulindac—Neuritis—Epirubicin—liver cancer	0.000753	0.00597	CcSEcCtD
Sulindac—Pleural effusion—Epirubicin—liver cancer	0.000735	0.00582	CcSEcCtD
Sulindac—Erythema multiforme—Sorafenib—liver cancer	0.000723	0.00572	CcSEcCtD
Sulindac—Tinnitus—Sorafenib—liver cancer	0.000713	0.00564	CcSEcCtD
Sulindac—Flushing—Sorafenib—liver cancer	0.000709	0.00562	CcSEcCtD
Sulindac—Vaginal haemorrhage—Doxorubicin—liver cancer	0.000703	0.00557	CcSEcCtD
Sulindac—Neuritis—Doxorubicin—liver cancer	0.000697	0.00552	CcSEcCtD
Sulindac—Ageusia—Epirubicin—liver cancer	0.000694	0.0055	CcSEcCtD
Sulindac—Arrhythmia—Sorafenib—liver cancer	0.000683	0.00541	CcSEcCtD
Sulindac—Pleural effusion—Doxorubicin—liver cancer	0.00068	0.00538	CcSEcCtD
Sulindac—Alopecia—Sorafenib—liver cancer	0.000675	0.00535	CcSEcCtD
Sulindac—Dysgeusia—Sorafenib—liver cancer	0.000652	0.00516	CcSEcCtD
Sulindac—Ageusia—Doxorubicin—liver cancer	0.000642	0.00509	CcSEcCtD
Sulindac—Anaemia—Sorafenib—liver cancer	0.000615	0.00487	CcSEcCtD
Sulindac—Glossitis—Epirubicin—liver cancer	0.00061	0.00483	CcSEcCtD
Sulindac—Angioedema—Sorafenib—liver cancer	0.000608	0.00481	CcSEcCtD
Sulindac—Syncope—Sorafenib—liver cancer	0.000597	0.00472	CcSEcCtD
Sulindac—Leukopenia—Sorafenib—liver cancer	0.000596	0.00472	CcSEcCtD
Sulindac—Loss of consciousness—Sorafenib—liver cancer	0.000585	0.00463	CcSEcCtD
Sulindac—Hypertension—Sorafenib—liver cancer	0.000574	0.00455	CcSEcCtD
Sulindac—Arthralgia—Sorafenib—liver cancer	0.000567	0.00449	CcSEcCtD
Sulindac—Myalgia—Sorafenib—liver cancer	0.000567	0.00449	CcSEcCtD
Sulindac—Glossitis—Doxorubicin—liver cancer	0.000565	0.00447	CcSEcCtD
Sulindac—Hyperkalaemia—Epirubicin—liver cancer	0.000553	0.00438	CcSEcCtD
Sulindac—Anaphylactic shock—Sorafenib—liver cancer	0.000543	0.0043	CcSEcCtD
Sulindac—Colitis—Epirubicin—liver cancer	0.00054	0.00428	CcSEcCtD
Sulindac—Shock—Sorafenib—liver cancer	0.000534	0.00423	CcSEcCtD
Sulindac—Thrombocytopenia—Sorafenib—liver cancer	0.000532	0.00421	CcSEcCtD
Sulindac—Aplastic anaemia—Epirubicin—liver cancer	0.000528	0.00418	CcSEcCtD
Sulindac—Anorexia—Sorafenib—liver cancer	0.000518	0.0041	CcSEcCtD
Sulindac—Coma—Epirubicin—liver cancer	0.000514	0.00407	CcSEcCtD
Sulindac—Hyperkalaemia—Doxorubicin—liver cancer	0.000511	0.00405	CcSEcCtD
Sulindac—Ecchymosis—Epirubicin—liver cancer	0.000509	0.00403	CcSEcCtD
Sulindac—Colitis—Doxorubicin—liver cancer	0.0005	0.00396	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000495	0.00392	CcSEcCtD
Sulindac—Aplastic anaemia—Doxorubicin—liver cancer	0.000489	0.00387	CcSEcCtD
Sulindac—Dyspnoea—Sorafenib—liver cancer	0.000484	0.00383	CcSEcCtD
Sulindac—Dyspepsia—Sorafenib—liver cancer	0.000478	0.00379	CcSEcCtD
Sulindac—Coma—Doxorubicin—liver cancer	0.000476	0.00377	CcSEcCtD
Sulindac—Decreased appetite—Sorafenib—liver cancer	0.000472	0.00374	CcSEcCtD
Sulindac—Ecchymosis—Doxorubicin—liver cancer	0.000471	0.00373	CcSEcCtD
Sulindac—Fatigue—Sorafenib—liver cancer	0.000468	0.00371	CcSEcCtD
Sulindac—Photosensitivity—Epirubicin—liver cancer	0.000465	0.00368	CcSEcCtD
Sulindac—Constipation—Sorafenib—liver cancer	0.000464	0.00368	CcSEcCtD
Sulindac—Vascular purpura—Epirubicin—liver cancer	0.000456	0.00361	CcSEcCtD
Sulindac—Hepatic failure—Epirubicin—liver cancer	0.000454	0.0036	CcSEcCtD
Sulindac—Cardiac failure congestive—Epirubicin—liver cancer	0.00045	0.00357	CcSEcCtD
Sulindac—Gastrointestinal pain—Sorafenib—liver cancer	0.000444	0.00352	CcSEcCtD
Sulindac—Dermatitis exfoliative—Epirubicin—liver cancer	0.000433	0.00343	CcSEcCtD
Sulindac—Urticaria—Sorafenib—liver cancer	0.000431	0.00342	CcSEcCtD
Sulindac—Photosensitivity—Doxorubicin—liver cancer	0.00043	0.00341	CcSEcCtD
Sulindac—Body temperature increased—Sorafenib—liver cancer	0.000429	0.0034	CcSEcCtD
Sulindac—Renal impairment—Epirubicin—liver cancer	0.000429	0.0034	CcSEcCtD
Sulindac—Purpura—Epirubicin—liver cancer	0.000424	0.00335	CcSEcCtD
Sulindac—Vascular purpura—Doxorubicin—liver cancer	0.000422	0.00334	CcSEcCtD
Sulindac—Hepatic failure—Doxorubicin—liver cancer	0.00042	0.00333	CcSEcCtD
Sulindac—Cardiac failure congestive—Doxorubicin—liver cancer	0.000417	0.0033	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000408	0.00323	CcSEcCtD
Sulindac—Dermatitis exfoliative—Doxorubicin—liver cancer	0.0004	0.00317	CcSEcCtD
Sulindac—Hypersensitivity—Sorafenib—liver cancer	0.0004	0.00317	CcSEcCtD
Sulindac—Renal impairment—Doxorubicin—liver cancer	0.000397	0.00314	CcSEcCtD
Sulindac—Purpura—Doxorubicin—liver cancer	0.000392	0.0031	CcSEcCtD
Sulindac—Asthenia—Sorafenib—liver cancer	0.00039	0.00309	CcSEcCtD
Sulindac—Pruritus—Sorafenib—liver cancer	0.000384	0.00304	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000378	0.00299	CcSEcCtD
Sulindac—Diarrhoea—Sorafenib—liver cancer	0.000372	0.00294	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000368	0.00291	CcSEcCtD
Sulindac—Gastritis—Epirubicin—liver cancer	0.000361	0.00286	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—liver cancer	0.00036	0.00285	CcSEcCtD
Sulindac—Dizziness—Sorafenib—liver cancer	0.000359	0.00284	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—liver cancer	0.000349	0.00277	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—liver cancer	0.000346	0.00274	CcSEcCtD
Sulindac—Vomiting—Sorafenib—liver cancer	0.000345	0.00273	CcSEcCtD
Sulindac—Rash—Sorafenib—liver cancer	0.000342	0.00271	CcSEcCtD
Sulindac—Dermatitis—Sorafenib—liver cancer	0.000342	0.00271	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00034	0.00269	CcSEcCtD
Sulindac—Headache—Sorafenib—liver cancer	0.00034	0.00269	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—liver cancer	0.000335	0.00265	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—liver cancer	0.000334	0.00265	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—liver cancer	0.000333	0.00264	CcSEcCtD
Sulindac—Dysuria—Epirubicin—liver cancer	0.00033	0.00261	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—liver cancer	0.00033	0.00261	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—liver cancer	0.000323	0.00256	CcSEcCtD
Sulindac—Nausea—Sorafenib—liver cancer	0.000323	0.00255	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—liver cancer	0.000322	0.00255	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—liver cancer	0.00032	0.00254	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—liver cancer	0.000318	0.00252	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—liver cancer	0.000317	0.00251	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000312	0.00247	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—liver cancer	0.00031	0.00246	CcSEcCtD
Sulindac—Renal failure—Epirubicin—liver cancer	0.000309	0.00245	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—liver cancer	0.000308	0.00244	CcSEcCtD
Sulindac—Jaundice—Epirubicin—liver cancer	0.000307	0.00243	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—liver cancer	0.000307	0.00243	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—liver cancer	0.000306	0.00242	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—liver cancer	0.000305	0.00242	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—liver cancer	0.000305	0.00242	CcSEcCtD
Sulindac—Sweating—Epirubicin—liver cancer	0.000302	0.00239	CcSEcCtD
Sulindac—Haematuria—Epirubicin—liver cancer	0.0003	0.00238	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—liver cancer	0.000298	0.00236	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—liver cancer	0.000297	0.00235	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—liver cancer	0.000295	0.00233	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—liver cancer	0.000294	0.00233	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—liver cancer	0.000293	0.00232	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000289	0.00229	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—liver cancer	0.000286	0.00227	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—liver cancer	0.000285	0.00226	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—liver cancer	0.000284	0.00225	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—liver cancer	0.000284	0.00225	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—liver cancer	0.000283	0.00224	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—liver cancer	0.000282	0.00224	CcSEcCtD
Sulindac—Sweating—Doxorubicin—liver cancer	0.000279	0.00221	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—liver cancer	0.000278	0.0022	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—liver cancer	0.000275	0.00217	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—liver cancer	0.000272	0.00216	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—liver cancer	0.000272	0.00215	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—liver cancer	0.000267	0.00211	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—liver cancer	0.000263	0.00209	CcSEcCtD
Sulindac—Flushing—Epirubicin—liver cancer	0.000262	0.00208	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—liver cancer	0.000261	0.00207	CcSEcCtD
Sulindac—Chills—Epirubicin—liver cancer	0.000253	0.00201	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—liver cancer	0.000252	0.002	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—liver cancer	0.000252	0.00199	CcSEcCtD
Sulindac—Alopecia—Epirubicin—liver cancer	0.00025	0.00198	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—liver cancer	0.000247	0.00196	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—liver cancer	0.000244	0.00193	CcSEcCtD
Sulindac—Flushing—Doxorubicin—liver cancer	0.000243	0.00192	CcSEcCtD
Sulindac—Flatulence—Epirubicin—liver cancer	0.000242	0.00192	CcSEcCtD
Sulindac—Tension—Epirubicin—liver cancer	0.000241	0.00191	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—liver cancer	0.000241	0.00191	CcSEcCtD
Sulindac—Nervousness—Epirubicin—liver cancer	0.000239	0.00189	CcSEcCtD
Sulindac—Chills—Doxorubicin—liver cancer	0.000235	0.00186	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—liver cancer	0.000234	0.00185	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—liver cancer	0.000232	0.00184	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—liver cancer	0.000231	0.00183	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—liver cancer	0.000228	0.00181	CcSEcCtD
Sulindac—Anaemia—Epirubicin—liver cancer	0.000227	0.0018	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—liver cancer	0.000224	0.00178	CcSEcCtD
Sulindac—Tension—Doxorubicin—liver cancer	0.000223	0.00177	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—liver cancer	0.000223	0.00176	CcSEcCtD
Sulindac—Malaise—Epirubicin—liver cancer	0.000222	0.00176	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—liver cancer	0.000221	0.00175	CcSEcCtD
Sulindac—Vertigo—Epirubicin—liver cancer	0.000221	0.00175	CcSEcCtD
Sulindac—Syncope—Epirubicin—liver cancer	0.000221	0.00175	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—liver cancer	0.00022	0.00174	CcSEcCtD
Sulindac—Palpitations—Epirubicin—liver cancer	0.000217	0.00172	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—liver cancer	0.000216	0.00171	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—liver cancer	0.000214	0.0017	CcSEcCtD
Sulindac—Convulsion—Epirubicin—liver cancer	0.000213	0.00169	CcSEcCtD
Sulindac—Hypertension—Epirubicin—liver cancer	0.000212	0.00168	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—liver cancer	0.000211	0.00167	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—liver cancer	0.00021	0.00167	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—liver cancer	0.000209	0.00166	CcSEcCtD
Sulindac—Chest pain—Epirubicin—liver cancer	0.000209	0.00166	CcSEcCtD
Sulindac—Myalgia—Epirubicin—liver cancer	0.000209	0.00166	CcSEcCtD
Sulindac—AKR1B1—embryo—liver cancer	0.000208	0.229	CbGeAlD
Sulindac—Discomfort—Epirubicin—liver cancer	0.000207	0.00164	CcSEcCtD
Sulindac—Malaise—Doxorubicin—liver cancer	0.000205	0.00162	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—liver cancer	0.000204	0.00162	CcSEcCtD
Sulindac—Syncope—Doxorubicin—liver cancer	0.000204	0.00162	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—liver cancer	0.000204	0.00161	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—liver cancer	0.000201	0.00159	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—liver cancer	0.000201	0.00159	CcSEcCtD
Sulindac—Oedema—Epirubicin—liver cancer	0.000201	0.00159	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—liver cancer	0.0002	0.00158	CcSEcCtD
Sulindac—Shock—Epirubicin—liver cancer	0.000197	0.00156	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—liver cancer	0.000197	0.00156	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—liver cancer	0.000197	0.00156	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—liver cancer	0.000196	0.00156	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—liver cancer	0.000196	0.00155	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—liver cancer	0.000194	0.00154	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—liver cancer	0.000194	0.00153	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—liver cancer	0.000194	0.00153	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—liver cancer	0.000194	0.00153	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—liver cancer	0.000191	0.00152	CcSEcCtD
Sulindac—Anorexia—Epirubicin—liver cancer	0.000191	0.00151	CcSEcCtD
Sulindac—Hypotension—Epirubicin—liver cancer	0.000188	0.00148	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—liver cancer	0.000186	0.00147	CcSEcCtD
Sulindac—Oedema—Doxorubicin—liver cancer	0.000186	0.00147	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000183	0.00145	CcSEcCtD
Sulindac—Shock—Doxorubicin—liver cancer	0.000183	0.00145	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—liver cancer	0.000182	0.00144	CcSEcCtD
Sulindac—Insomnia—Epirubicin—liver cancer	0.000182	0.00144	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—liver cancer	0.000181	0.00144	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—liver cancer	0.00018	0.00143	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—liver cancer	0.00018	0.00142	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—liver cancer	0.000179	0.00142	CcSEcCtD
Sulindac—Somnolence—Epirubicin—liver cancer	0.000178	0.00141	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—liver cancer	0.000177	0.0014	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—liver cancer	0.000177	0.0014	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—liver cancer	0.000174	0.00138	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—liver cancer	0.000174	0.00137	CcSEcCtD
Sulindac—Fatigue—Epirubicin—liver cancer	0.000173	0.00137	CcSEcCtD
Sulindac—Constipation—Epirubicin—liver cancer	0.000172	0.00136	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000169	0.00134	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—liver cancer	0.000168	0.00133	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—liver cancer	0.000167	0.00132	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—liver cancer	0.000166	0.00131	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—liver cancer	0.000165	0.00131	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—liver cancer	0.000165	0.00131	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—liver cancer	0.000164	0.0013	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—liver cancer	0.000163	0.00129	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—liver cancer	0.000161	0.00128	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—liver cancer	0.00016	0.00127	CcSEcCtD
Sulindac—Urticaria—Epirubicin—liver cancer	0.000159	0.00126	CcSEcCtD
Sulindac—Constipation—Doxorubicin—liver cancer	0.000159	0.00126	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—liver cancer	0.000159	0.00126	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—liver cancer	0.000153	0.00121	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—liver cancer	0.000152	0.0012	CcSEcCtD
Sulindac—MAPK3—embryo—liver cancer	0.000151	0.166	CbGeAlD
Sulindac—Hypersensitivity—Epirubicin—liver cancer	0.000148	0.00117	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—liver cancer	0.000148	0.00117	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—liver cancer	0.000147	0.00116	CcSEcCtD
Sulindac—Asthenia—Epirubicin—liver cancer	0.000144	0.00114	CcSEcCtD
Sulindac—Pruritus—Epirubicin—liver cancer	0.000142	0.00112	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—liver cancer	0.000137	0.00109	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—liver cancer	0.000137	0.00108	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—liver cancer	0.000133	0.00105	CcSEcCtD
Sulindac—Dizziness—Epirubicin—liver cancer	0.000133	0.00105	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—liver cancer	0.000131	0.00104	CcSEcCtD
Sulindac—Vomiting—Epirubicin—liver cancer	0.000128	0.00101	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—liver cancer	0.000127	0.00101	CcSEcCtD
Sulindac—Rash—Epirubicin—liver cancer	0.000127	0.001	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—liver cancer	0.000126	0.001	CcSEcCtD
Sulindac—Headache—Epirubicin—liver cancer	0.000126	0.000996	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—liver cancer	0.000123	0.000972	CcSEcCtD
Sulindac—Nausea—Epirubicin—liver cancer	0.000119	0.000944	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—liver cancer	0.000118	0.000935	CcSEcCtD
Sulindac—Rash—Doxorubicin—liver cancer	0.000117	0.000927	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—liver cancer	0.000117	0.000926	CcSEcCtD
Sulindac—Headache—Doxorubicin—liver cancer	0.000116	0.000921	CcSEcCtD
Sulindac—ALB—gall bladder—liver cancer	0.000114	0.125	CbGeAlD
Sulindac—Nausea—Doxorubicin—liver cancer	0.00011	0.000873	CcSEcCtD
Sulindac—AKR1B1—liver—liver cancer	9.63e-05	0.106	CbGeAlD
Sulindac—PPARD—liver—liver cancer	7.57e-05	0.0832	CbGeAlD
Sulindac—MAPK3—liver—liver cancer	6.98e-05	0.0767	CbGeAlD
Sulindac—PTGS2—gall bladder—liver cancer	6.19e-05	0.0679	CbGeAlD
Sulindac—PTGS2—embryo—liver cancer	3.92e-05	0.0431	CbGeAlD
Sulindac—ALB—liver—liver cancer	3.33e-05	0.0366	CbGeAlD
Sulindac—CYP1A2—liver—liver cancer	2.19e-05	0.024	CbGeAlD
Sulindac—CYP1A1—liver—liver cancer	2.16e-05	0.0237	CbGeAlD
Sulindac—PTGS2—liver—liver cancer	1.81e-05	0.0199	CbGeAlD
Sulindac—MAPK3—Immune System—PIK3CD—liver cancer	1.15e-05	4.48e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—liver cancer	1.14e-05	4.44e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GOT2—liver cancer	1.13e-05	4.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—liver cancer	1.13e-05	4.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—SERPINE1—liver cancer	1.13e-05	4.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—liver cancer	1.12e-05	4.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CSF2—liver cancer	1.12e-05	4.38e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—liver cancer	1.12e-05	4.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—RAF1—liver cancer	1.12e-05	4.37e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTP1—liver cancer	1.11e-05	4.32e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NR1H4—liver cancer	1.11e-05	4.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—H2AFX—liver cancer	1.11e-05	4.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—liver cancer	1.1e-05	4.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CB—liver cancer	1.09e-05	4.27e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HMOX1—liver cancer	1.09e-05	4.26e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.09e-05	4.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTA3—liver cancer	1.09e-05	4.25e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	1.09e-05	4.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PRKCE—liver cancer	1.08e-05	4.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—liver cancer	1.08e-05	4.2e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP2E1—liver cancer	1.07e-05	4.16e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—liver cancer	1.06e-05	4.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CD—liver cancer	1.06e-05	4.13e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HPGDS—liver cancer	1.06e-05	4.13e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CD—liver cancer	1.05e-05	4.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.05e-05	4.1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.05e-05	4.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—liver cancer	1.05e-05	4.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SERPINE1—liver cancer	1.05e-05	4.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—liver cancer	1.05e-05	4.08e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SERPINE1—liver cancer	1.04e-05	4.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.04e-05	4.05e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PSMA4—liver cancer	1.04e-05	4.04e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PSMD10—liver cancer	1.04e-05	4.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.03e-05	4.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—RAF1—liver cancer	1.02e-05	4e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTM1—liver cancer	1.02e-05	3.97e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GOT2—liver cancer	1.01e-05	3.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—liver cancer	1.01e-05	3.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TERT—liver cancer	1e-05	3.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CB—liver cancer	1e-05	3.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MTOR—liver cancer	1e-05	3.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYCS—liver cancer	9.98e-06	3.89e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTA4—liver cancer	9.96e-06	3.89e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GGT1—liver cancer	9.79e-06	3.82e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GOT1—liver cancer	9.79e-06	3.82e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	9.74e-06	3.8e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTA2—liver cancer	9.71e-06	3.79e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—liver cancer	9.7e-06	3.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—liver cancer	9.69e-06	3.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—liver cancer	9.68e-06	3.78e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP1A1—liver cancer	9.65e-06	3.76e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.59e-06	3.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—liver cancer	9.5e-06	3.7e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP2E1—liver cancer	9.47e-06	3.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—RAF1—liver cancer	9.46e-06	3.69e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PSMD10—liver cancer	9.44e-06	3.68e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PSMA4—liver cancer	9.44e-06	3.68e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—H2AFX—liver cancer	9.41e-06	3.67e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—RAF1—liver cancer	9.4e-06	3.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1B—liver cancer	9.39e-06	3.66e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTA1—liver cancer	9.37e-06	3.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—liver cancer	9.27e-06	3.62e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NAT2—liver cancer	9.26e-06	3.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTOR—liver cancer	9.24e-06	3.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CB—liver cancer	9.24e-06	3.6e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—liver cancer	9.23e-06	3.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—liver cancer	9.19e-06	3.58e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GOT2—liver cancer	9.18e-06	3.58e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CB—liver cancer	9.18e-06	3.58e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	9.17e-06	3.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KDR—liver cancer	9.16e-06	3.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK14—liver cancer	9.1e-06	3.55e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MTHFR—liver cancer	9e-06	3.51e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—liver cancer	8.94e-06	3.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ESR1—liver cancer	8.93e-06	3.48e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.91e-06	3.47e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALDOB—liver cancer	8.88e-06	3.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTNNB1—liver cancer	8.87e-06	3.46e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	8.87e-06	3.46e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYCS—liver cancer	8.86e-06	3.45e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARA—liver cancer	8.83e-06	3.44e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—F2—liver cancer	8.82e-06	3.44e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTP1—liver cancer	8.8e-06	3.43e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GGT1—liver cancer	8.69e-06	3.39e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GOT1—liver cancer	8.69e-06	3.39e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HMOX1—liver cancer	8.68e-06	3.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1B—liver cancer	8.67e-06	3.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1A—liver cancer	8.66e-06	3.38e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP2E1—liver cancer	8.63e-06	3.37e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—liver cancer	8.55e-06	3.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTHFR—liver cancer	8.53e-06	3.33e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TERT—liver cancer	8.51e-06	3.32e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CRABP1—liver cancer	8.47e-06	3.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK8—liver cancer	8.46e-06	3.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CG—liver cancer	8.44e-06	3.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APC—liver cancer	8.44e-06	3.29e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—liver cancer	8.43e-06	3.29e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.36e-06	3.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—liver cancer	8.19e-06	3.19e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	8.14e-06	3.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—liver cancer	8.08e-06	3.15e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYCS—liver cancer	8.07e-06	3.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1A—liver cancer	8e-06	3.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—liver cancer	7.93e-06	3.09e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.93e-06	3.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GGT1—liver cancer	7.92e-06	3.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GOT1—liver cancer	7.92e-06	3.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—liver cancer	7.81e-06	3.04e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—liver cancer	7.73e-06	3.01e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HMOX1—liver cancer	7.7e-06	3e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1A1—liver cancer	7.66e-06	2.99e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	7.63e-06	2.97e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—liver cancer	7.56e-06	2.95e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—liver cancer	7.54e-06	2.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CD—liver cancer	7.42e-06	2.89e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HPGDS—liver cancer	7.4e-06	2.89e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.36e-06	2.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SERPINE1—liver cancer	7.34e-06	2.86e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—liver cancer	7.3e-06	2.85e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—liver cancer	7.26e-06	2.83e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—liver cancer	7.17e-06	2.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—liver cancer	7.17e-06	2.8e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—liver cancer	7.16e-06	2.79e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—liver cancer	7.14e-06	2.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—liver cancer	7.14e-06	2.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—liver cancer	7.14e-06	2.78e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—liver cancer	7.12e-06	2.78e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HMOX1—liver cancer	7.02e-06	2.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARA—liver cancer	7.01e-06	2.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—liver cancer	6.74e-06	2.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.71e-06	2.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—liver cancer	6.67e-06	2.6e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CD—liver cancer	6.65e-06	2.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—liver cancer	6.64e-06	2.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—liver cancer	6.63e-06	2.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RAF1—liver cancer	6.62e-06	2.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.62e-06	2.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—liver cancer	6.62e-06	2.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PSMA4—liver cancer	6.6e-06	2.57e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PSMD10—liver cancer	6.6e-06	2.57e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—liver cancer	6.57e-06	2.56e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—liver cancer	6.56e-06	2.56e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—liver cancer	6.54e-06	2.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MTOR—liver cancer	6.47e-06	2.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CB—liver cancer	6.47e-06	2.52e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GOT2—liver cancer	6.42e-06	2.5e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—liver cancer	6.34e-06	2.47e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CD—liver cancer	6.3e-06	2.46e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.3e-06	2.46e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SERPINE1—liver cancer	6.23e-06	2.43e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARA—liver cancer	6.22e-06	2.43e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1A1—liver cancer	6.2e-06	2.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—liver cancer	6.17e-06	2.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—liver cancer	6.13e-06	2.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—liver cancer	6.1e-06	2.38e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—liver cancer	6.09e-06	2.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—liver cancer	6.07e-06	2.37e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2E1—liver cancer	6.04e-06	2.35e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—liver cancer	6e-06	2.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—liver cancer	5.95e-06	2.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—liver cancer	5.94e-06	2.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—liver cancer	5.91e-06	2.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.84e-06	2.28e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CB—liver cancer	5.79e-06	2.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—liver cancer	5.79e-06	2.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—liver cancer	5.79e-06	2.26e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—liver cancer	5.78e-06	2.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—liver cancer	5.78e-06	2.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—liver cancer	5.73e-06	2.24e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARA—liver cancer	5.67e-06	2.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYCS—liver cancer	5.65e-06	2.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—liver cancer	5.64e-06	2.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—liver cancer	5.63e-06	2.2e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—RAF1—liver cancer	5.63e-06	2.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—liver cancer	5.62e-06	2.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1A—liver cancer	5.6e-06	2.18e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—liver cancer	5.6e-06	2.18e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.59e-06	2.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GGT1—liver cancer	5.54e-06	2.16e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GOT1—liver cancer	5.54e-06	2.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTOR—liver cancer	5.49e-06	2.14e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CB—liver cancer	5.49e-06	2.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK8—liver cancer	5.47e-06	2.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—liver cancer	5.45e-06	2.13e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—liver cancer	5.41e-06	2.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—liver cancer	5.4e-06	2.11e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—liver cancer	5.33e-06	2.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CD—liver cancer	5.28e-06	2.06e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—liver cancer	5.21e-06	2.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—liver cancer	5.21e-06	2.03e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—liver cancer	5.18e-06	2.02e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—liver cancer	5.15e-06	2.01e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—liver cancer	5.14e-06	2.01e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.09e-06	1.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—liver cancer	5.05e-06	1.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—liver cancer	5e-06	1.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—liver cancer	4.99e-06	1.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—liver cancer	4.98e-06	1.94e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—liver cancer	4.98e-06	1.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—liver cancer	4.95e-06	1.93e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HMOX1—liver cancer	4.91e-06	1.91e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—liver cancer	4.87e-06	1.9e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—liver cancer	4.86e-06	1.89e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1A—liver cancer	4.76e-06	1.86e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—liver cancer	4.69e-06	1.83e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CD—liver cancer	4.68e-06	1.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—liver cancer	4.64e-06	1.81e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—liver cancer	4.63e-06	1.81e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—liver cancer	4.62e-06	1.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CB—liver cancer	4.6e-06	1.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—liver cancer	4.6e-06	1.79e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—liver cancer	4.57e-06	1.78e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—liver cancer	4.57e-06	1.78e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1A1—liver cancer	4.34e-06	1.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—liver cancer	4.29e-06	1.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CD—liver cancer	4.27e-06	1.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—liver cancer	4.24e-06	1.66e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CB—liver cancer	4.08e-06	1.59e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—liver cancer	4.04e-06	1.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARA—liver cancer	3.97e-06	1.55e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—liver cancer	3.94e-06	1.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—liver cancer	3.94e-06	1.54e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—liver cancer	3.93e-06	1.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—liver cancer	3.81e-06	1.49e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CB—liver cancer	3.72e-06	1.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—liver cancer	3.65e-06	1.42e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—liver cancer	3.64e-06	1.42e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.56e-06	1.39e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—liver cancer	3.53e-06	1.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—liver cancer	3.49e-06	1.36e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—liver cancer	3.4e-06	1.32e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—liver cancer	3.35e-06	1.31e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—liver cancer	3.28e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—liver cancer	3.22e-06	1.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—liver cancer	3.1e-06	1.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CD—liver cancer	2.99e-06	1.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—liver cancer	2.96e-06	1.16e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—liver cancer	2.95e-06	1.15e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—liver cancer	2.89e-06	1.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—liver cancer	2.8e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—liver cancer	2.74e-06	1.07e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CB—liver cancer	2.6e-06	1.02e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—liver cancer	2.49e-06	9.71e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—liver cancer	2.29e-06	8.93e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—liver cancer	2.27e-06	8.85e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—liver cancer	2.03e-06	7.93e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—liver cancer	1.85e-06	7.23e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—liver cancer	1.59e-06	6.19e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—liver cancer	1.3e-06	5.06e-06	CbGpPWpGaD
